LOXL1 and cancer: It was observed that adaptive immune cell, notably CD8 + T cells known for their positive impact on survival and immunotherapy response in various cancers (Bruni et al. 2020), was markedly lower in cases with heightened LOXL1 expression (Fig. 5A).